CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 132 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2021. The put-call ratio across all filers is 1.14 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,371,377 | -10.5% | 49,832 | +10.3% | 0.00% | 0.0% |
| Q2 2023 | $1,532,482 | -30.3% | 45,166 | -26.1% | 0.00% | 0.0% |
| Q1 2023 | $2,197,586 | -16.5% | 61,078 | +4.1% | 0.00% | -50.0% |
| Q4 2022 | $2,633,050 | +71.0% | 58,651 | +7.7% | 0.00% | +100.0% |
| Q3 2022 | $1,539,670 | +11.7% | 54,464 | +8.6% | 0.00% | 0.0% |
| Q2 2022 | $1,378,913 | -36.9% | 50,133 | -21.1% | 0.00% | 0.0% |
| Q1 2022 | $2,186,828 | +142.2% | 63,511 | +172.7% | 0.00% | 0.0% |
| Q4 2021 | $903,000 | -28.4% | 23,286 | -0.4% | 0.00% | 0.0% |
| Q3 2021 | $1,262,000 | +70.5% | 23,379 | +5.6% | 0.00% | 0.0% |
| Q2 2021 | $740,000 | – | 22,135 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,605,390 | $71,552,232 | 10.98% |
| Octagon Capital Advisors LP | 761,398 | $33,935,509 | 5.28% |
| TSP Capital Management Group, LLC | 269,895 | $12,029,225 | 4.50% |
| Redmile Group, LLC | 1,977,451 | $88,134,991 | 3.60% |
| COMMODORE CAPITAL LP | 495,823 | $22,099 | 3.33% |
| Tri Locum Partners LP | 176,109 | $7,849,000 | 3.18% |
| ACUTA CAPITAL PARTNERS, LLC | 115,000 | $5,125,550 | 3.15% |
| Ikarian Capital, LLC | 267,476 | $11,921,406 | 2.88% |
| RTW INVESTMENTS, LP | 3,084,215 | $137,463,463 | 2.81% |
| Eversept Partners, LP | 558,774 | $24,904,557 | 2.18% |